WEGOVY® FLEXTOUCH® 0.25mg (Italian)

WEGOVY® FLEXTOUCH 0.25mg (ITALIAN) – Key Features and Benefits

Wegovy® FlexTouch® is a once-weekly injectable treatment containing semaglutide, designed to support weight loss and maintenance. It mimics a natural hormone (GLP-1) that helps control appetite, making users feel fuller and less hungry. The 0.25mg dose is used as the initial step in the dosing escalation schedule.

• Active Ingredient: Semaglutide, a GLP-1 receptor agonist

• Indicated for: Obesity, overweight with comorbidities, and cardiovascular risk reduction

• Initial dose: 0.25 mg once weekly, part of a 16-week titration plan

• Administered via: Subcutaneous injection using a pre-filled FlexTouch® pen

• Helps with: Appetite suppression, weight loss, reduced food cravings

• Use in Adolescents: Approved for ages ≥12 years with body weight >60 kg

• Cardiovascular benefit: Reduces heart disease-related events in adults with BMI ≥27 kg/m² and heart history

WEGOVY® FLEXTOUCH 0.25mg (ITALIAN) – Indications

Wegovy® is indicated as an adjunct to a reduced-calorie diet and increased physical activity. It is used to manage chronic weight issues in both adults and adolescents, including reducing cardiovascular risk in specific patient groups.

• Adults:

  • BMI ≥30 (obesity)

  • BMI 27–29.9 with weight-related comorbidities

  • With heart disease and BMI ≥27, even without diabetes

• Adolescents (≥12 years):

  • With obesity and body weight >60 kg

  • Continued use only if ≥5% BMI reduction is seen after 12 weeks on 2.4 mg

• Not recommended for:

  • Type 1 diabetes

  • Use with other weight-loss products

  • Children under 12 years

WEGOVY® FLEXTOUCH 0.25mg (ITALIAN) – Ingredients

The 0.25 mg dose of Wegovy® FlexTouch® contains both active and inactive components necessary for stability and effectiveness.

• Active ingredient:

  • Semaglutide (0.68 mg/mL; 1.0 mg per 1.5 mL pen)

• Inactive ingredients:

  • Dibasic sodium phosphate dihydrate

  • Propylene glycol

  • Phenol

  • Water for injections

  • Sodium hydroxide/hydrochloric acid (pH adjustment)

• Formulation:

  • Clear, colorless solution

  • Pre-filled pen contains 4 doses

• Sodium content:

  • Less than 23 mg per dose (considered sodium-free)

WEGOVY® FLEXTOUCH 0.25mg (ITALIAN) – How To Use

Wegovy® is administered once a week by subcutaneous injection. The 0.25 mg dose is used during the first 4 weeks of treatment to minimize gastrointestinal side effects before dose escalation.

• Administration site: Abdomen, thigh, or upper arm (under the skin only)

• Frequency: Once per week, same day if possible

• Dose escalation schedule:

  • Week 1–4: 0.25 mg

  • Week 5–8: 0.5 mg

  • Week 9–12: 1.0 mg

  • Week 13–16: 1.7 mg

  • Week 17+: 2.4 mg maintenance

• Instructions:

  • Do not inject into veins or muscles

  • Can be taken any time of day, regardless of meals

• Missed dose:

  • Take within 5 days, otherwise skip and resume regular schedule

• Storage:

  • Refrigerate (2–8°C) or keep at room temp (below 30°C) for up to 6 weeks

WEGOVY® FLEXTOUCH 0.25mg (ITALIAN) – Side Effects

Wegovy® can cause a range of side effects, mostly gastrointestinal. Most are mild and temporary, but some require urgent medical attention.

Common and less serious:

• Very common (≥1 in 10): Nausea, vomiting, diarrhea, constipation, headache, abdominal pain

• Common (≤1 in 10): Indigestion, dizziness, bloating, burping, fatigue, flatulence, dry mouth

• Uncommon (≤1 in 100): Fast heart rate, altered pancreas tests, stomach emptying delay

Serious (Seek immediate help):

• Acute pancreatitis: Severe abdominal pain radiating to the back

• Severe allergic reaction: Swelling of face, lips, throat, breathing difficulty, rash

• Bowel obstruction: Severe constipation with bloating, vomiting

• Diabetic retinopathy worsening: In patients with Type 2 diabetes

Risk of hypoglycemia:

• Especially if taken with insulin or sulfonylureas

• Warning signs: Cold sweats, shakiness, dizziness, blurred vision, confusion

WEGOVY® FLEXTOUCH 0.25mg (ITALIAN) – Clinical Studies

Wegovy®’s effectiveness and safety were established through long-term clinical trials involving adults and adolescents. These studies showed consistent, clinically meaningful weight loss and cardiovascular risk reduction.

• Primary mechanism: Mimics GLP-1 to reduce appetite and food intake

• Clinically proven outcomes:

  • Significant weight loss when used with diet and exercise

  • Improved cardiovascular outcomes in high-risk patients

• Adolescents:

  • Must demonstrate ≥5% BMI reduction after 12 weeks on 2.4 mg to continue

• Safety monitoring:

  • Ongoing due to recent approval and evolving data (additional monitoring status)

WEGOVY® FLEXTOUCH 0.25mg (ITALIAN) – Manufacturer Information

Wegovy® is manufactured and distributed by Novo Nordisk, a leading global pharmaceutical company specializing in metabolic disorders.

• Manufacturer: Novo Nordisk A/S

• Distributor (Australia): Novo Nordisk Pharmaceuticals Pty. Ltd., North Sydney, NSW

• Distributor (New Zealand): Novo Nordisk Pharmaceuticals Ltd., Auckland

• Trademarks: Wegovy®, FlexTouch®, NovoFine®

• Support program: WegovyCare® (Australia) – https://wegovycare.com.au

WEGOVY® FLEXTOUCH 0.25mg (ITALIAN) – FAQ

Is Wegovy® 0.25 mg effective for weight loss?
Yes, but it’s intended as a starting dose. The 0.25 mg dose is used for the first 4 weeks to minimize nausea before escalating to the effective 2.4 mg dose.

How long should I stay on the 0.25 mg dose?
Only for the first 4 weeks. After that, the dose increases every 4 weeks up to 2.4 mg weekly.

Can I use Wegovy® 0.25 mg long-term?
No, it’s a starter dose. The long-term therapeutic dose is 2.4 mg weekly.

Does Wegovy® 0.25 mg have side effects?
Yes. Nausea, vomiting, diarrhea, and constipation are common, especially in the first weeks. These usually improve over time.

Can I skip a dose of Wegovy®?
Yes. If it’s been ≤5 days, inject it ASAP. If it’s been >5 days, skip and resume the regular schedule.

What is Wegovy® used for?
It is used for chronic weight management, cardiovascular risk reduction, and appetite regulation.

Can adolescents use Wegovy®?
Yes, if ≥12 years old and >60 kg, but they must show progress (≥5% BMI loss after 12 weeks at full dose) to continue.